• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Invo Bioscience signs European distribution deal

Invo Bioscience signs European distribution deal

November 13, 2019 By Sean Whooley

INVO BioscienceInvo Bioscience (OTCQB:IVOB) announced that it entered into commercialization agreements covering Turkey and Jordan to support the company’s expansion into Eurasia.

The commercialization agreements are in place to spread the Lakewood Ranch, Fla.–based company’s InvoCell in vivo fertility system to the Eurasia area. Invo Bioscience said research shows that an estimated 15% to 20% of the Turkish population suffers from difficulty conceiving, which experts attribute to environmental factors.

The company entered into distribution agreements with Orcan Medical for commercialization in Turkey. Orcan is slated to become the exclusive commercial partner for InvoCell in Turkey, contingent upon minimum purchase and other requirements.

Biovate is set to be the exclusive distribution partner for InvoCell in Jordan after standard administrative requirements for supplying the device in the country are fulfilled. Financial terms of the agreements in Turkey and Jordan were not disclosed, but Invo Biosciences expects distribution to begin in both countries in 2020.

InvoCell is designed to enable egg fertilization and early embryo development to take place in a woman’s body. The company said it is approximately half the cost of traditional IVF treatment and has shown comparable pregnancy rates while it can be administered without the need to for overhead of IVF centers.

InvoCell won FDA de novo approval in November 2015 and was launched in the U.S. in April 2016. Currently, it is distributed throughout the U.S. under an $8 million agreement with Ferring Pharmaceuticals, into which the companies entered in January of this year. The device previously held CE Mark approval from 2008 to 2012, but the company shifted commercial focus from Europe to the U.S. for several years, until it received CE Mark approval again last month.

“We are extremely pleased to have established commercialization agreements with Orcan Medical and Biovate to expand our reach into the Eurasian market,” Invo Bioscience director of business development said in a news release. “Infertility is an issue throughout the entire world. Unfortunately, due to the high cost and limited access of existing treatments, many go without treatment. We believe the InvoCell solution solves these important issues and we look forward to working with the teams at Orcan and Biovate to bring our technology to the people of Turkey and Jordan.”

“The Invo Bioscience team has done a great job leveraging their previous relationships to create commercialization agreements to benefit the company,” added Invo Bioscience CEO Steve Shum. “We believe 2020 is shaping up to be an exciting year as we look to significantly expand our international efforts.”

Filed Under: Business/Financial News, Gynecological Tagged With: INVO Bioscience

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy